Acalculous Cholecystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acalculous cholecystitis markets reached a value of US$ 330 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 850 Million by 2034, exhibiting a growth rate (CAGR) of 8.99% during 2024-2034.
The acalculous cholecystitis market has been comprehensively analyzed in IMARC's new report titled "Acalculous Cholecystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acalculous cholecystitis (AC) refers to a medical condition of acute inflammation and distention of the gallbladder without any evidence of gallstones or cystic duct obstruction. The symptoms of acalculous cholecystitis can be similar to those of calculous cholecystitis, but in this case, there are no stones present in the gallbladder. Some of the common signs indicative of acalculous cholecystitis are severe abdominal pain, which is typically located in the right upper quadrant or epigastric region, nausea, vomiting, fever, jaundice, loss of appetite, tenderness in the abdomen, etc. The diagnosis of the ailment usually involves a combination of clinical evaluation and imaging tests. The physician generally starts by obtaining a thorough medical history and performing a physical exam to assess for symptoms such as abdominal pain, tenderness, and fever. Numerous imaging tests, including an abdominal ultrasound or computed tomography (CT) scan, are used to confirm the diagnosis and evaluate the severity of the condition. Additionally, blood tests are also utilized to assess for signs of infection or inflammation.
The rising incidences of several associated risk factors, such as gallbladder injury, bacterial infections, ischemia, etc., which cause gallbladder inflammation, are primarily driving the acalculous cholecystitis market. In addition to this, the escalating utilization of percutaneous cholecystostomy for draining the gallbladder in order to relieve symptoms of AC and prevent complications, including gangrene or perforation of the gallbladder, is further bolstering the market growth. Moreover, the widespread adoption of endoscopic retrograde cholangiopancreatography (ERCP) for identifying biliary obstruction, which can help to alleviate symptoms and prevent complications, is also augmenting the market. Apart from this, the increasing usage of magnetic resonance cholangiopancreatography (MRCP), a non-invasive imaging modality, to visualize the bile ducts and pancreas for confirming AC in cases where the ultrasound is inconclusive, is creating a positive outlook for the market. Additionally, several key players are making extensive investments in the development of narrow-spectrum antibiotics to target specific pathogens and minimize the effect of resistance. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of laparoscopic cholecystectomy on account of its numerous associated benefits, such as reduced scarring, quicker recovery, and a shorter hospital stay compared to open surgery procedures, is expected to drive the acalculous cholecystitis market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the acalculous cholecystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acalculous cholecystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acalculous cholecystitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acalculous cholecystitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acalculous cholecystitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acalculous cholecystitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the acalculous cholecystitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acalculous cholecystitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acalculous cholecystitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acalculous cholecystitis across the seven major markets?
What is the size of the acalculous cholecystitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acalculous cholecystitis?
What will be the growth rate of patients across the seven major markets?
Acalculous Cholecystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acalculous cholecystitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acalculous cholecystitis market?
What are the key regulatory events related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by status related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by phase related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by route of administration related to the acalculous cholecystitis market?
The acalculous cholecystitis market has been comprehensively analyzed in IMARC's new report titled "Acalculous Cholecystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acalculous cholecystitis (AC) refers to a medical condition of acute inflammation and distention of the gallbladder without any evidence of gallstones or cystic duct obstruction. The symptoms of acalculous cholecystitis can be similar to those of calculous cholecystitis, but in this case, there are no stones present in the gallbladder. Some of the common signs indicative of acalculous cholecystitis are severe abdominal pain, which is typically located in the right upper quadrant or epigastric region, nausea, vomiting, fever, jaundice, loss of appetite, tenderness in the abdomen, etc. The diagnosis of the ailment usually involves a combination of clinical evaluation and imaging tests. The physician generally starts by obtaining a thorough medical history and performing a physical exam to assess for symptoms such as abdominal pain, tenderness, and fever. Numerous imaging tests, including an abdominal ultrasound or computed tomography (CT) scan, are used to confirm the diagnosis and evaluate the severity of the condition. Additionally, blood tests are also utilized to assess for signs of infection or inflammation.
The rising incidences of several associated risk factors, such as gallbladder injury, bacterial infections, ischemia, etc., which cause gallbladder inflammation, are primarily driving the acalculous cholecystitis market. In addition to this, the escalating utilization of percutaneous cholecystostomy for draining the gallbladder in order to relieve symptoms of AC and prevent complications, including gangrene or perforation of the gallbladder, is further bolstering the market growth. Moreover, the widespread adoption of endoscopic retrograde cholangiopancreatography (ERCP) for identifying biliary obstruction, which can help to alleviate symptoms and prevent complications, is also augmenting the market. Apart from this, the increasing usage of magnetic resonance cholangiopancreatography (MRCP), a non-invasive imaging modality, to visualize the bile ducts and pancreas for confirming AC in cases where the ultrasound is inconclusive, is creating a positive outlook for the market. Additionally, several key players are making extensive investments in the development of narrow-spectrum antibiotics to target specific pathogens and minimize the effect of resistance. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of laparoscopic cholecystectomy on account of its numerous associated benefits, such as reduced scarring, quicker recovery, and a shorter hospital stay compared to open surgery procedures, is expected to drive the acalculous cholecystitis market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the acalculous cholecystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acalculous cholecystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acalculous cholecystitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acalculous cholecystitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acalculous cholecystitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acalculous cholecystitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the acalculous cholecystitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acalculous cholecystitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acalculous cholecystitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acalculous cholecystitis across the seven major markets?
What is the size of the acalculous cholecystitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acalculous cholecystitis?
What will be the growth rate of patients across the seven major markets?
Acalculous Cholecystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acalculous cholecystitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acalculous cholecystitis market?
What are the key regulatory events related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by status related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by phase related to the acalculous cholecystitis market?
What is the structure of clinical trial landscape by route of administration related to the acalculous cholecystitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACALCULOUS CHOLECYSTITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACALCULOUS CHOLECYSTITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACALCULOUS CHOLECYSTITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACALCULOUS CHOLECYSTITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACALCULOUS CHOLECYSTITIS - UNMET NEEDS
10 ACALCULOUS CHOLECYSTITIS - KEY ENDPOINTS OF TREATMENT
11 ACALCULOUS CHOLECYSTITIS - MARKETED PRODUCTS
11.1 List of Acalculous Cholecystitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACALCULOUS CHOLECYSTITIS - PIPELINE DRUGS
12.1 List of Acalculous Cholecystitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACALCULOUS CHOLECYSTITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACALCULOUS CHOLECYSTITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACALCULOUS CHOLECYSTITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acalculous Cholecystitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acalculous Cholecystitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acalculous Cholecystitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acalculous Cholecystitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acalculous Cholecystitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acalculous Cholecystitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acalculous Cholecystitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acalculous Cholecystitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acalculous Cholecystitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acalculous Cholecystitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acalculous Cholecystitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acalculous Cholecystitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acalculous Cholecystitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acalculous Cholecystitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acalculous Cholecystitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acalculous Cholecystitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acalculous Cholecystitis - Access and Reimbursement Overview
16 ACALCULOUS CHOLECYSTITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACALCULOUS CHOLECYSTITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACALCULOUS CHOLECYSTITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACALCULOUS CHOLECYSTITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACALCULOUS CHOLECYSTITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACALCULOUS CHOLECYSTITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACALCULOUS CHOLECYSTITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACALCULOUS CHOLECYSTITIS - UNMET NEEDS
10 ACALCULOUS CHOLECYSTITIS - KEY ENDPOINTS OF TREATMENT
11 ACALCULOUS CHOLECYSTITIS - MARKETED PRODUCTS
11.1 List of Acalculous Cholecystitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACALCULOUS CHOLECYSTITIS - PIPELINE DRUGS
12.1 List of Acalculous Cholecystitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACALCULOUS CHOLECYSTITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACALCULOUS CHOLECYSTITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACALCULOUS CHOLECYSTITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acalculous Cholecystitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acalculous Cholecystitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acalculous Cholecystitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acalculous Cholecystitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acalculous Cholecystitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acalculous Cholecystitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acalculous Cholecystitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acalculous Cholecystitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acalculous Cholecystitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acalculous Cholecystitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acalculous Cholecystitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acalculous Cholecystitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acalculous Cholecystitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acalculous Cholecystitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acalculous Cholecystitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acalculous Cholecystitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acalculous Cholecystitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acalculous Cholecystitis - Access and Reimbursement Overview
16 ACALCULOUS CHOLECYSTITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACALCULOUS CHOLECYSTITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACALCULOUS CHOLECYSTITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
